StefanSKachalaMDFACS(He/Him)

PubMed

• 14 citations
  Value of routine timed barium esophagram follow-up in achalasia after myotomy
  Stefan S. Kachala, Thomas W. Rice, Mark E. Baker, Jeevanantham Rajeswaran, Prashanthi N. Thota
  The Journal of Thoracic and Cardiovascular Surgery. 2018-08-01
• 26 citations
  Surgical Management of Sternoclavicular Joint Infections.
  Stefan S. Kachala, Desmond M. D’Souza, Lucileia Teixeira-Johnson, Sudish C. Murthy, Siva Raja
  The Annals of Thoracic Surgery. 2016-06-01
• 4 citations
  Lung transplantation for multifocal lung adenocarcinoma (multifocal lung carcinoma).
  Stefan S. Kachala, Sudish C. Murthy
  Thoracic Surgery Clinics. 2014-11-01

Journal Articles

• Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-free and Overall Survival in Early-Stage Lung Adenocarcinoma  
  Kachala S, Bograd AJ, Villena-Vargas J, Suzuki K, Servais EL, Kadota K, Chou JF, Sima CS, Vertes E, Rusch VW, Travis WD, Sadelain M, Adusumilli PS, Clinical Cancer Research, 1/15/2014
• Lung Transplantation for Multifocal Lung Adenocarcinoma  
  Kachala SS and Murthy SC, Thoracic Surgery Clinics, 1/1/2014
• Adusumilli PS High-SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: Supportive evidence to reclassify pleomorphic as non-...  
  Kadota K, Kachala SS, Nitadori JI, Suzuki K, Dunphy MP, Sima CS, Travis WD, Rusch VW, Journal of Thoracic Oncology, 1/1/2012
• A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma  
  Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS, Moreira AL, Yoshizawa A, Riely GJ, Rusch VW, Adusumilli PS, Travis WD, Modern Pathology, 1/1/2012
• Prognostic Immune Markers in Non-Small Cell Lung Cancer  
  Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS, Clinical Cancer Research, 1/15/2011
• Recovery and Biodistribution of Ex-vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2R-null mice  
  Ghinassi B, Ferro L, Masiello F, Tirelli V, Sanchez M, Migliaccio G, Whitsett C, Kachala S, Riviere I, Sadelain M, and Migliaccio AR, Stem Cell International, 1/1/2011
• Palliation and Pleurodesis in Malignant Pleural Effusion: The Role for Tunneled Pleural Catheters  
  Suzuki K, Servais EL, Rizk NP, Solomon SB, Sima CS, Park BJ, Kachala SS, Zlobinsky M, Rusch VW, Adusumilli PS, Journal of Thoracic Oncology, 1/1/2011
• The ageing physician  
  Morales EA, Kachala SS, Bograd AJ, Adusumilli PS, National Medical Journal of India, 1/1/2011
• Expression signature developed from a complex series of mouse models accurately predicts human breast cancer survival  
  He M, Mangiameli D, Kachala SS, Hunter K, Gillespie J, Bian X, Shen HCJ, Libutti S, Clinical Cancer Research, 1/1/2010
• Doctor, did you wash your hands?  
  Rodriguez LA, Kachala SS, Adusumilli PS, National Medical Journal of India, 1/1/2010
• Therapeutic sentinel lymph node imaging  
  Kachala SS, Servais EL, Park BJ, Rusch VW, Adusumilli PS, Seminars in Thoracic and Cardiovascular Surgery, 1/1/2009
• Health insurance reform  
  Servais EL, Kachala SS, Adusumill PS, National Medical Journal of India, 1/1/2009
• Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature  
  Paoloni M, Tandle A, Mazcko C, Hanna E, Kachala S, Leblanc A, Newman S, Vail D, Henry, C, Thamm D, Sorenmo K, Hajitou A, Pasqualini R, Arap W, Khanna C, Libutti S, Journal of Translational Medicine, 1/18/2007
• Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma  
  Mangiameli DP, Blansfield JA, Kachala S, Lorang D, Schafer PH, Muller GW, Stirling DI and Libutti SK, Journal of Translational Medicine, 1/1/2007
• Join now to see all

Books/Book Chapters

• Current Protocols in Pharmacology 
  Chapter: Pre-Clinical Mouse Models of Primary and Metastatic Pleural Cancers of the Lung and Breast and the Use of Bioluminescent Imaging to Monitor Pleural Tumor Burden. 
  Servais EL, Colovos C, Kachala SS, Adusumilli PS2011
• Current Surgical Therapy 
  Chapter: Ablative Therapies in Benign and Malignant Breast Disease. 
  Kachala SS, Simmons RMEditors: Cameron JL.Mosby, Philadelphia2010
• Sabiston and Spencer's Surgery of the Chest 
  Chapter: Lung Cancer: Multimodal Therapy. 
  Kachala SS, Mason DP, and Murthy SCEditors: Selke F, del Nido PE, and Swanson SJ.Saunders-Elsevier, PhiladelphiaEdition 9th,2005

Abstracts/Posters

• Mesothelin Expression Promotes An Aggressive Phenotype Of Non-Small Cell Lung Cancer (NSCLC).
  Vertes EL, Kachala S, Servais E, Rodriguez L, Rusch W, Sadelain M, Adusumilli P, Oncology-Tumor Biology Forum of the 6th Annual Academic Surgical Congress (ASC), Huntington Beach, CA, 1/1/2011
• Mesothelin expression promotes invasive phenotype and matrix metalloproteinase secretion in pleural mesothelioma.
  Servais E, Colovos C, Kachala S, Rodriguez L, Kadota K, Rusch V, Sadelain M, Adusumilli P, Basic Science Forum at the 10th International Conference of the International Mesothelioma Interest Group, Kyoto, Japan, 1/31/2010
• Ghinassi B, Ferro L, Kachala S, Riviere I, Sadelain M, Migliaccio AF, Basic Science Forum of the 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, 1/4/2010
• Outcomes of indwelling tunneled pleural catheters for malignant pleural effusion: the role for surgical evaluation.
  Suzuki K, Servais E, Sima C, Kachala S, Rizk N, Park, B, Rusch V, Adusumilli P, Surgical Forum Program at the American College of Surgeons 96th Annual Clinical Congress, Washington, DC, 1/3/2010
• Phase I study of thermally sensitive liposomes containing doxorubicin (ThermoDox [TD]) given during radiofrequency ablation (RFA) in patients with unresectable hepatic...
  Wood B, Neeman Z, Eugeni M, Locklin J, Dromi S, Kachala S, Prabhakar R, Hahne W, Libutti KS, Gastrointestinal Cancers Symposium-ASCO, 1/1/2007
• Join now to see all

Lectures

• Beneficial Role of Antigen Commensalism in Mesothelin-Targeted T-cell Therapy for Lung Adenocarcinoma. 
  1/27/2015
• Mesothelin Overexpression Imparts an Aggressive Phenotype and Decreases Recurrence-Free Survival in Early Stage Lung Adenocarcinoma. 
  Minneapolis, MN - 1/4/2013
• Mesothelin is a commonly expressed tumor marker in lung adenocarcinoma (LAC) that imparts an aggressive phenotype-a candidate molecular target. 
  Amsterdam, Netherlands - 1/3/2011